This review summarizes preclinical and clinical studies investigating stem cell-based therapies as an alternative treatment for chronic chagasic cardiomyopathy.
Stem cell therapies for chronic chagasic cardiomyopathy remain investigational; leaves open need for randomized efficacy and safety trials.
Chagas disease is caused by Trypanosoma cruzi and can lead to a dilated cardiomyopathy decades after the prime infection by the parasite. As with other dilated cardiomyopathies, conventional pharmacologic therapies are not always effective and as heart failure progresses patients need heart transplantation. Therefore alternative therapies are highly desirable and cell-based therapies have been investigated in preclinical and clinical studies. In this paper we review the main findings of such studies and discuss future directions for stem cell-based therapies in chronic chagasic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Carvalho et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: